Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDR Alder Biopharmaceuticals	$18.88	$18.88	$8.39 ▼ $19.12	$1.58B	2.64	5.12 million shs	N/A
CORT Corcept Therapeutics	$71.88 -0.2%	$72.67	$31.46 ▼ $117.33	$7.62B	0.15	1.19 million shs	679,544 shs
ESPR Esperion Therapeutics	$1.19 -4.0%	$1.01	$0.69 ▼ $3.94	$235.86M	0.7	4.75 million shs	2.09 million shs
LGND Ligand Pharmaceuticals	$121.70 -2.6%	$109.40	$90.29 ▼ $129.90	$2.35B	0.84	116,645 shs	106,482 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDR Alder Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CORT Corcept Therapeutics	0.00%	-1.06%	+0.98%	+4.75%	+134.75%
ESPR Esperion Therapeutics	0.00%	+1.62%	-0.83%	+16.67%	-49.58%
LGND Ligand Pharmaceuticals	0.00%	+6.40%	+6.33%	+16.72%	+26.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDR Alder Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	4.8161 of 5 stars	3.5	3.0	0.0	4.3	2.2	4.2	1.9
ESPR Esperion Therapeutics	4.0161 of 5 stars	3.4	2.0	0.0	3.9	2.5	1.7	0.6
LGND Ligand Pharmaceuticals	4.1075 of 5 stars	2.5	1.0	0.0	4.4	2.1	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDR Alder Biopharmaceuticals	0.00	N/A	N/A	N/A
CORT Corcept Therapeutics	3.00	Buy	$138.25	92.33% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	488.24% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	20.93% Upside

Current Analyst Ratings Breakdown

Latest ESPR, CORT, ALDR, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDR Alder Biopharmaceuticals	$1.62M	977.10	N/A	N/A	$1.61 per share	11.73
CORT Corcept Therapeutics	$675.04M	11.29	$1.24 per share	57.87	$6.49 per share	11.08
ESPR Esperion Therapeutics	$332.31M	0.71	$0.02 per share	49.53	($1.97) per share	-0.60
LGND Ligand Pharmaceuticals	$167.13M	14.05	$1.61 per share	75.74	$43.95 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDR Alder Biopharmaceuticals	-$296.43M	-$4.87	N/A	N/A	N/A	N/A	-226.13%	-66.86%	N/A
CORT Corcept Therapeutics	$141.21M	$1.16	61.97	38.85	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	0.00	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	32.80	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest ESPR, CORT, ALDR, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
8/4/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDR Alder Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDR Alder Biopharmaceuticals	1.74	8.94	8.94
CORT Corcept Therapeutics	N/A	3.07	2.96
ESPR Esperion Therapeutics	N/A	1.18	0.81
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDR Alder Biopharmaceuticals	N/A
CORT Corcept Therapeutics	93.61%
ESPR Esperion Therapeutics	47.39%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ALDR Alder Biopharmaceuticals	15.40%
CORT Corcept Therapeutics	20.80%
ESPR Esperion Therapeutics	1.70%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDR Alder Biopharmaceuticals	202	83.84 million	N/A	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

ESPR, CORT, ALDR, and LGND Headlines

Recent News About These Companies

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq

July 12 at 1:54 PM | nasdaq.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 Shares

July 12 at 6:25 AM | insidertrades.com

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

July 11 at 8:14 PM | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

July 11 at 7:52 PM | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11 at 5:49 PM | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10 at 11:40 PM | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10 at 8:00 AM | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9, 2025 | marketbeat.com

Brokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14

July 8, 2025 | americanbankingnews.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 4, 2025 | marketbeat.com

Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July

July 2, 2025 | finanznachrichten.de

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals

July 2, 2025 | quiverquant.comQ

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

July 2, 2025 | globenewswire.com

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

July 2, 2025 | globenewswire.com

Lisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 29, 2025 | marketbeat.com

LGND Ligand Pharmaceuticals Incorporated - Seeking Alpha

June 26, 2025 | seekingalpha.com

Andrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 26, 2025 | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in Stock

June 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, CORT, ALDR, and LGND Company Descriptions

Alder Biopharmaceuticals NASDAQ:ALDR

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Corcept Therapeutics NASDAQ:CORT

$71.88 -0.13 (-0.18%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$71.35 -0.53 (-0.74%)

As of 07/11/2025 07:48 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Esperion Therapeutics NASDAQ:ESPR

$1.19 -0.05 (-4.03%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.42%)

As of 07/11/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Ligand Pharmaceuticals NASDAQ:LGND

$121.70 -3.28 (-2.62%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$121.72 +0.02 (+0.02%)

As of 07/11/2025 07:06 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time